Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics

The Diagnosis Confirmation Model (DCM) includes a dual-pricing mechanism designed to support value-based pricing of novel antibiotics while improving the alignment of financial incentives with their optimal use in patients at high risk of drug-resistant infections. DCM is a market-based model and co...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of law, medicine & ethics medicine & ethics, 2018-06, Vol.46 (1_suppl), p.66-74
Main Authors: Lum, Ka, Bhatti, Taimur, Holland, Silas, Guthrie, Mark, Sassman, Stephanie
Format: Article
Language:English
Subjects:
Antibiotics
Antimicrobial agents
Bacteria
Bacterial infections
Cost control
Drug resistance
Drug stores
Feedback
Focus groups
Health technology assessment
Hospital costs
Incentives
Infections
Innovations
Medical diagnosis
Multidrug resistant organisms
Pathogens
Patients
Policy making
R&D
Reimbursement
Research & development
Technological change
Value
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Diagnosis Confirmation Model (DCM) includes a dual-pricing mechanism designed to support value-based pricing of novel antibiotics while improving the alignment of financial incentives with their optimal use in patients at high risk of drug-resistant infections. DCM is a market-based model and complementary to delinked models. Policymakers interested in stimulating antibiotic innovation could consider tailoring the DCM to their reimbursement systems and incorporating it into the suite of incentives to improve the economics of antibiotics.
ISSN:1073-1105
1748-720X
DOI:10.1177/1073110518782917